RH (RH) At $86.63 Forms Top; 2 Bullish Analysts Covering Merrimack Pharmaceuticals, Inc. (MACK)

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Logo

Among 5 analysts covering Merrimack Pharmaceuticals (NASDAQ:MACK), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Merrimack Pharmaceuticals had 10 analyst reports since August 12, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Monday, September 11 by Robert W. Baird. Robert W. Baird maintained Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) on Friday, October 13 with “Hold” rating. As per Wednesday, August 12, the company rating was reinitiated by Oppenheimer. The rating was maintained by Oppenheimer with “Outperform” on Tuesday, October 27. The stock has “Neutral” rating by JP Morgan on Friday, October 7. The firm earned “Outperform” rating on Wednesday, August 12 by Mizuho. Mizuho maintained Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) rating on Wednesday, December 23. Mizuho has “Buy” rating and $13.0 target. The stock of Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) earned “Neutral” rating by Robert W. Baird on Friday, May 27. The firm has “Neutral” rating given on Friday, August 19 by BTIG Research. The firm earned “Buy” rating on Tuesday, August 11 by Brean Capital. See Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) latest ratings:

13/10/2017 Broker: Robert W. Baird Rating: Hold New Target: $15.0 Maintain

RH (RH) formed multiple top with $94.43 target or 9.00% above today’s $86.63 share price. RH (RH) has $1.86B valuation. The stock decreased 1.39% or $1.22 during the last trading session, reaching $86.63. About 595,302 shares traded. RH (NYSE:RH) has risen 105.26% since April 12, 2017 and is uptrending. It has outperformed by 93.71% the S&P500.

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company has market cap of $114.48 million. The company's therapeutic oncology candidates in clinical development include MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer; and MM-141 that is in Phase II clinical trial for treating previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1. It has a 0.24 P/E ratio. The Company’s therapeutic oncology candidates also comprise MM-310 for treating solid tumors; and MM-151 that has completed a Phase I clinical trial for treating solid tumors.

Investors sentiment is 0 in Q4 2017. Its the same as in 2017Q3. It has no change, as 2 investors sold Merrimack Pharmaceuticals, Inc. shares while 0 reduced holdings. only 0 funds opened positions while 0 raised stakes. 27,550 shares or 99.05% less from 2.91 million shares in 2017Q3 were reported. Horrell Capital Management, a Arkansas-based fund reported 50 shares. 27,500 are owned by Dekabank Deutsche Girozentrale.

The stock increased 4.13% or $0.34 during the last trading session, reaching $8.58. About 169,297 shares traded or 2.11% up from the average. Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) has declined 61.33% since April 12, 2017 and is downtrending. It has underperformed by 72.88% the S&P500.

Investors sentiment decreased to 0 in 2017 Q4. Its down 1.00, from 1 in 2017Q3. It turned negative, as 1 investors sold RH shares while 0 reduced holdings. 0 funds opened positions while 0 raised stakes. 8,264 shares or 90.30% less from 85,222 shares in 2017Q3 were reported. First Financial Bank Of Omaha has 0.04% invested in RH (NYSE:RH). Gemmer Asset Management Llc owns 64 shares or 0% of their US portfolio.

Among 26 analysts covering Restoration Hardware Holdings (NYSE:RH), 8 have Buy rating, 1 Sell and 17 Hold. Therefore 31% are positive. Restoration Hardware Holdings had 99 analyst reports since July 31, 2015 according to SRatingsIntel. Deutsche Bank maintained RH (NYSE:RH) rating on Wednesday, March 30. Deutsche Bank has “Buy” rating and $50 target. The firm has “Neutral” rating by Buckingham Research given on Friday, October 7. On Friday, March 24 the stock rating was maintained by Guggenheim with “Buy”. The stock of RH (NYSE:RH) has “Hold” rating given on Friday, September 9 by Deutsche Bank. The stock of RH (NYSE:RH) has “Buy” rating given on Wednesday, November 15 by Buckingham Research. The firm has “Neutral” rating given on Thursday, February 25 by Robert W. Baird. Telsey Advisory Group maintained RH (NYSE:RH) rating on Friday, October 16. Telsey Advisory Group has “Outperform” rating and $119 target. The company was downgraded on Thursday, June 9 by Raymond James. Cowen & Co maintained the stock with “Market Perform” rating in Thursday, February 25 report. On Tuesday, September 1 the stock rating was downgraded by Zacks to “Buy”.

Since December 13, 2017, it had 0 insider purchases, and 3 selling transactions for $5.64 million activity. Shares for $1.06 million were sold by DEMILIO MARK S on Monday, April 2. Shares for $2.19M were sold by Boone Karen on Wednesday, December 13.

RH (NYSE:RH) Ratings Chart